ID: ALA125231

Max Phase: Preclinical

Molecular Formula: C33H37BrClN5O6S

Molecular Weight: 747.11

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  CCCCc1nn(-c2cc(NC(=O)CC)ccc2Br)c(=O)n1Cc1ccc(-c2ccccc2S(=O)(=O)NC(=O)OC(C)(C)C)cc1Cl

Standard InChI:  InChI=1S/C33H37BrClN5O6S/c1-6-8-13-29-37-40(27-19-23(16-17-25(27)34)36-30(41)7-2)32(43)39(29)20-22-15-14-21(18-26(22)35)24-11-9-10-12-28(24)47(44,45)38-31(42)46-33(3,4)5/h9-12,14-19H,6-8,13,20H2,1-5H3,(H,36,41)(H,38,42)

Standard InChI Key:  ZKJPLGJFGCDALG-UHFFFAOYSA-N

Associated Targets(non-human)

Angiotensin II type 1a (AT-1a) receptor 1700 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Angiotensin II type 2 (AT-2) receptor 803 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Angiotensin II receptor (AT-1) type-1 1480 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Angiotensin II receptor 1735 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 747.11Molecular Weight (Monoisotopic): 745.1336AlogP: 7.07#Rotatable Bonds: 11
Polar Surface Area: 141.39Molecular Species: ACIDHBA: 9HBD: 2
#RO5 Violations: 2HBA (Lipinski): 11HBD (Lipinski): 2#RO5 Violations (Lipinski): 3
CX Acidic pKa: 2.91CX Basic pKa: CX LogP: 8.09CX LogD: 7.14
Aromatic Rings: 4Heavy Atoms: 47QED Weighted: 0.17Np Likeness Score: -1.40

References

1. Chang LL, Ashton WT, Flanagan KL, Chen TB, O'Malley SS, Zingaro GJ, Kivlighn SD, Siegl PK, Lotti VJ, Chang RS..  (1995)  Potent and orally active angiotensin II receptor antagonists with equal affinity for human AT1 and AT2 subtypes.,  38  (19): [PMID:7562905] [10.1021/jm00019a004]
2. Sharma MC, Kohli DV.  (2012)  Insight into the structural requirement of aryltriazolinone derivatives as angiotensin II AT1 receptor: 2D and 3D-QSAR k-Nearest Neighbor Molecular Field Analysis approach,  21  (10): [10.1007/s00044-011-9815-x]

Source